Influenza Antiviral Resistance Testing in New York and Wisconsin, 2006 to 2008: Methodology and Surveillance Data

Laplante, Jennifer; Marshall, Steven A.; Shudt, Matthew; Van, Tam T.; Mingle, Lisa A.; Shult, Peter; George, Kirsten St.

doi:10.1128/jcm.01993-08

Cited by 21 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Note that while subtyping can serve as a surrogate for antiviral resistance once the antiviral susceptibility profiles of circulating subtypes are well characterized, one important caveat is the regional and local variability in antiviral resistance in different subtypes, which can potentially limit extrapolation of national antiviral resistance data for formulating local public health recommendations for antiviral use. For example, while 10.8% of H1N1 influenza viruses were reported nationally to be adamantane resistant in 2007 to 2008, only 1.2% were resistant in Wisconsin and New York (84). Most importantly, subtype-guided antiviral choices should be made carefully in the context of the pathogenicity and clinical profile of a novel virus, which may dictate the level of specificity required for the diagnosis.…”

Section: Multiplex Detectionmentioning

confidence: 99%

Update on Influenza Diagnostics: Lessons from the Novel H1N1 Influenza A Pandemic

2012

View full text Add to dashboard Cite

SUMMARY The menu of diagnostic tools that can be utilized to establish a diagnosis of influenza is extensive and includes classic virology techniques as well as new and emerging methods. This review of how the various existing diagnostic methods have been utilized, first in the context of a rapidly evolving outbreak of novel influenza virus and then during the different subsequent phases and waves of the pandemic, demonstrates the unique roles, advantages, and limitations of each of these methods. Rapid antigen tests were used extensively throughout the pandemic. Recognition of the low negative predictive values of these tests is important. Private laboratories with preexisting expertise, infrastructure, and resources for rapid development, validation, and implementation of laboratory-developed assays played an unprecedented role in helping to meet the diagnostic demands during the pandemic. FDA-cleared assays remain an important element of the diagnostic armamentarium during a pandemic, and a process must be developed with the FDA to allow manufacturers to modify these assays for detection of novel strains in a timely fashion. The need and role for subtyping of influenza viruses and antiviral susceptibility testing will likely depend on qualitative (circulating subtypes and their resistance patterns) and quantitative (relative prevalence) characterization of influenza viruses circulating during future epidemics and pandemics.

show abstract

Section: Multiplex Detectionmentioning

confidence: 99%

Update on Influenza Diagnostics: Lessons from the Novel H1N1 Influenza A Pandemic

2012

View full text Add to dashboard Cite

show abstract

“…Two external negative controls of 5 μL ultra-pure water were also run with each batch to detect possible cross-contamination. Extracted influenza A and B RNA from all clinical specimens was quantified by real-time PCR as previously described (Ghedin et al, 2009), and H275 sequences in the NA genes of both seasonal and pandemic A/H1N1 were confirmed by pyrosequencing or dideoxy sequencing (Laplante et al, 2009). …”

Section: Methodsmentioning

confidence: 99%

“…Aliquots of serially-diluted influenza samples ranging from 10 3 –10 6 gc mL −1 were extracted, then amplified and hybridized in duplicate to the microarray: the experiment was repeated three times on three separate days. Extracted RNA was also quantified by influenza A and B real-time RT-PCR, in duplicate, as previously described (Laplante et al, 2009). Limits of detection were determined as the lowest concentration in which target probes displayed an SNR value ≥3 on both replicates on each of the three days.…”

Section: Methodsmentioning

confidence: 99%

Development and clinical testing of a simple, low-density gel element array for influenza identification, subtyping, and H275Y detection

Chandler

Griesemer

Knickerbocker

et al. 2014

Journal of Virological Methods

Self Cite

View full text Add to dashboard Cite

The objectives of this study were to develop a user-friendly, gel element microarray test for influenza virus detection, subtyping, and neuraminidase inhibitor resistance detection, assess the performance characteristics of the assay, and perform a clinical evaluation on retrospective nasopharyngeal swab specimens. A streamlined microarray workflow enabled a single user to run up to 24 tests in an 8 hour shift. The most sensitive components of the test were the primers and probes targeting the A/H1pdm09 HA gene with an analytical limit of detection (LoD) <100 gene copies (gc) per reaction. LoDs for all targets in nasopharyngeal swab samples were ≤ 1000 gc, with the exception of one target in the seasonal A/H1N1 subtype. Seasonal H275Y variants were detectable in a mixed population when present at > 5% with wild type virus, while the 2009 pandemic H1N1 H275Y variant was detectable at ≤1% in a mixture with pandemic wild type virus. Influenza typing and sub typing results concurred with those obtained with real-time RT-PCR assays on more than 97% of the samples tested. The results demonstrate that a large panel of single-plex, real-time RT-PCR tests can be translated to an easy-to-use, sensitive, and specific microarray test for potential diagnostic use.

show abstract

“…However, in the 91 samples collected between 2007 and 2008, 13 were found resistant to oseltamivir, due to the H274Y substitution (Laplante et al, 2009). …”

Section: The Resistance To Oseltamivirmentioning

confidence: 99%

Influenza a (H1n1) and the Resistance to Oseltamivir

Gomes¹,

Neves²

2012

VR&R

View full text Add to dashboard Cite

Influenza is an acute infection of the respiratory system usually self-limiting, evolving towards complete cure due to the immunological response of the infected organism, but that can have serious complications, such as pneumonia and death. It is a disease widely distributed around the world, associated with several pandemics for over a century. The most recent pandemic occurred in 2009, when a new strain of influenza A (H1N1) virus caused an outbreak in Veracruz, Mexico, and rapidly spread though all the continents, causing over 12 thousand deaths in less than a year. Considering that this new strain of the virus is only sensitive to neuraminidase inhibitors (oseltamivir and zanamivir) and that the protocol of the World Health Organization recommends the use of oseltamivir as a single drug therapy, this study was performed with the intention of collecting and compiling data about the occurrence of resistance to this medication, in particular due to a H274Y substitution. In addition to mapping the occurrence of resistant virus, data was also collect about the person-to-person transmission of the virus with the mutation H274Y, as well as about the association of the appearance of resistance with the use of the drug.

show abstract

Influenza Antiviral Resistance Testing in New York and Wisconsin, 2006 to 2008: Methodology and Surveillance Data

Cited by 21 publications

References 24 publications

Update on Influenza Diagnostics: Lessons from the Novel H1N1 Influenza A Pandemic

Update on Influenza Diagnostics: Lessons from the Novel H1N1 Influenza A Pandemic

Development and clinical testing of a simple, low-density gel element array for influenza identification, subtyping, and H275Y detection

Influenza a (H1n1) and the Resistance to Oseltamivir

Contact Info

Product

Resources

About